WO2025149737 - INTERLEUKIN-1 BETA BINDING ANTIBODY
National phase entry is expected:
Publication Number
WO/2025/149737
Publication Date
17.07.2025
International Application No.
PCT/GB2025/000001
International Filing Date
01.01.2025
Title **
[English]
INTERLEUKIN-1 BETA BINDING ANTIBODY
[French]
ANTICORPS DE LIAISON À L'INTERLEUKINE-1 BÊTA
Applicants **
WOTHERSPOON, Hugh Robert
Inventors
WOTHERSPOON, Hugh Robert
Priority Data
2400340.2
10.01.2024
GB
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Natural Person
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1880 | |
| EPO | Filing, Examination, Granting | 6201 | |
| Japan | Filing, Examination, Granting | 1937 | |
| South Korea | Filing, Examination, Granting | 1631 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
16,389
Contact Us
Abstract[English]
An IL-1β binding antibody or functional fragment thereof for use in reducing the risk of having an event of acute pancreatitis in a patient who has had a prior event of acute pancreatitis.[French]
L'invention concerne un anticorps de liaison à IL-1β ou un fragment fonctionnel de celui-ci destiné à être utilisé pour réduire le risque chez un patient qui a subi un événement antérieur de pancréatite aiguë de subir un événement de pancréatite aiguë.